114 related articles for article (PubMed ID: 33639190)
1. Acute patient-reported intestinal toxicity in whole pelvis IMRT for prostate cancer: Bowel dose-volume effect quantification in a multicentric cohort study.
Bresolin A; Faiella A; Garibaldi E; Munoz F; Cante D; Vavassori V; Waskiewicz JM; Girelli G; Avuzzi B; Villa E; Magli A; Noris Chiorda B; Gatti M; Ferella L; Maggio A; Landoni V; Aimonetto S; Sini C; Rancati T; Sanguineti G; Valdagni R; Di Muzio N; Fiorino C; Cozzarini C
Radiother Oncol; 2021 May; 158():74-82. PubMed ID: 33639190
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy: First quantification of bowel dose-volume effects.
Sini C; Noris Chiorda B; Gabriele P; Sanguineti G; Morlino S; Badenchini F; Cante D; Carillo V; Gaetano M; Giandini T; Landoni V; Maggio A; Perna L; Petrucci E; Sacco V; Valdagni R; Rancati T; Fiorino C; Cozzarini C
Radiother Oncol; 2017 Aug; 124(2):296-301. PubMed ID: 28739383
[TBL] [Abstract][Full Text] [Related]
3. Dose-volume relationships for acute bowel toxicity in patients treated with pelvic nodal irradiation for prostate cancer.
Fiorino C; Alongi F; Perna L; Broggi S; Cattaneo GM; Cozzarini C; Di Muzio N; Fazio F; Calandrino R
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):29-35. PubMed ID: 19467803
[TBL] [Abstract][Full Text] [Related]
4. Anatomical and clinical predictors of acute bowel toxicity in whole pelvis irradiation for prostate cancer with Tomotherapy.
Longobardi B; Berardi G; Fiorino C; Alongi F; Cozzarini C; Deli A; La Macchia M; Perna L; Di Muzio NG; Calandrino R
Radiother Oncol; 2011 Dec; 101(3):460-4. PubMed ID: 21864924
[TBL] [Abstract][Full Text] [Related]
5. Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
Hong TS; Tomé WA; Jaradat H; Raisbeck BM; Ritter MA
Acta Oncol; 2006; 45(6):717-27. PubMed ID: 16938815
[TBL] [Abstract][Full Text] [Related]
6. Worsening of 2-year patient-reported intestinal functionality after radiotherapy for prostate cancer including pelvic node irradiation.
Sanguineti G; Pavarini M; Munoz F; Magli A; Cante D; Garibaldi E; Gebbia A; Noris Chiorda B; Girelli G; Villa E; Faiella A; Magdalena Waskiewicz J; Avuzzi B; Pastorino A; Moretti E; Rago L; Statuto T; Gatti M; Rancati T; Valdagni R; Luigi Vavassori V; Gisella Di Muzio N; Fiorino C; Cozzarini C
Radiother Oncol; 2024 Mar; 192():110088. PubMed ID: 38199284
[TBL] [Abstract][Full Text] [Related]
7. The role and strategy of IMRT in radiotherapy of pelvic tumors: Dose escalation and critical organ sparing in prostate cancer.
Liu YM; Shiau CY; Lee ML; Huang PI; Hsieh CM; Chen PH; Lin YH; Wang LW; Yen SH
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1113-23. PubMed ID: 17197126
[TBL] [Abstract][Full Text] [Related]
8. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
[TBL] [Abstract][Full Text] [Related]
9. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
10. Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation.
Sini C; Fiorino C; Perna L; Noris Chiorda B; Deantoni CL; Bianchi M; Sacco V; Briganti A; Montorsi F; Calandrino R; Di Muzio N; Cozzarini C
Radiother Oncol; 2016 Jan; 118(1):79-84. PubMed ID: 26702990
[TBL] [Abstract][Full Text] [Related]
11. Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate--first results of the PLATIN 1 trial.
Habl G; Katayama S; Uhl M; Kessel KA; Edler L; Debus J; Herfarth K; Sterzing F
BMC Cancer; 2015 Nov; 15():868. PubMed ID: 26547188
[TBL] [Abstract][Full Text] [Related]
12. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
[TBL] [Abstract][Full Text] [Related]
13. Pelvic bone marrow dose-volume predictors of late lymphopenia following pelvic lymph node radiation therapy for prostate cancer.
Pavarini M; Alborghetti L; Aimonetto S; Maggio A; Landoni V; Ferrari P; Bianculli A; Petrucci E; Cicchetti A; Farina B; Ubeira-Gabellini MG; Salmoiraghi P; Moretti E; Avuzzi B; Giandini T; Munoz F; Magli A; Sanguineti G; Magdalena Waskiewicz J; Rago L; Cante D; Girelli G; Vavassori V; Di Muzio NG; Rancati T; Cozzarini C; Fiorino C
Radiother Oncol; 2024 Jun; 195():110230. PubMed ID: 38503355
[TBL] [Abstract][Full Text] [Related]
14. Predictors of acute bowel toxicity in patients treated with IMRT whole pelvis irradiation after prostatectomy.
Perna L; Alongi F; Fiorino C; Broggi S; Cattaneo Giovanni M; Cozzarini C; Di Muzio N; Calandrino R
Radiother Oncol; 2010 Oct; 97(1):71-5. PubMed ID: 20307910
[TBL] [Abstract][Full Text] [Related]
15. Late toxicity and quality of life with prostate only or whole pelvic radiation therapy in high risk prostate cancer (POP-RT): A randomised trial.
Murthy V; Maitre P; Bhatia J; Kannan S; Krishnatry R; Prakash G; Bakshi G; Pal M; Menon S; Mahantshetty U
Radiother Oncol; 2020 Apr; 145():71-80. PubMed ID: 31923712
[TBL] [Abstract][Full Text] [Related]
16. Hematologic Toxicity in Patients Treated With Postprostatectomy Whole-Pelvis Irradiation With Different Intensity Modulated Radiation Therapy Techniques Is Not Negligible and Is Prolonged: Preliminary Results of a Longitudinal, Observational Study.
Cozzarini C; Noris Chiorda B; Sini C; Fiorino C; Briganti A; Montorsi F; Di Muzio N
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):690-5. PubMed ID: 27131081
[TBL] [Abstract][Full Text] [Related]
17. Quality of life after whole pelvic versus prostate-only external beam radiotherapy for prostate cancer: a matched-pair comparison.
Pinkawa M; Piroth MD; Holy R; Fischedick K; Klotz J; Székely-Orbán D; Eble MJ
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):23-8. PubMed ID: 20832182
[TBL] [Abstract][Full Text] [Related]
18. IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy.
Alongi F; Fiorino C; Cozzarini C; Broggi S; Perna L; Cattaneo GM; Calandrino R; Di Muzio N
Radiother Oncol; 2009 Nov; 93(2):207-12. PubMed ID: 19766338
[TBL] [Abstract][Full Text] [Related]
19. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer.
Wang-Chesebro A; Xia P; Coleman J; Akazawa C; Roach M
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):654-62. PubMed ID: 17011444
[TBL] [Abstract][Full Text] [Related]
20. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
Arcangeli S; Saracino B; Petrongari MG; Gomellini S; Marzi S; Landoni V; Gallucci M; Sperduti I; Arcangeli G
Radiother Oncol; 2007 Aug; 84(2):148-55. PubMed ID: 17692416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
